New Patent Issued for Core Rare Disease Target Indication for Crofelemer

Napo has approximately 230 patents issued and pending

Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025

SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan’s Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar’s novel plant-based prescription drug.

“We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS,” said Lisa Conte, Jaguar’s founder, president, and CEO.

Crofelemer is a novel plant-based prescription drug that has shown promising results in the treatment of SBS, bile acid diarrhea, and other gastrointestinal disorders. The new patent issued to Napo Pharmaceuticals further solidifies their position in the market and provides additional protection for their core rare disease target indication.

Jaguar Health, Inc. is dedicated to improving the lives of patients with rare diseases through innovative treatments like crofelemer. By securing patents for their products, they can continue to develop new therapies and bring hope to those suffering from debilitating conditions.

How This Will Affect Me

As a patient with a rare gastrointestinal disorder, the issuance of this patent could mean access to a new and potentially effective treatment option. Crofelemer has shown promise in clinical trials for SBS and other conditions, and this new patent could pave the way for its approval and availability to patients like me.

How This Will Affect the World

The development of new treatments for rare diseases is crucial for improving healthcare outcomes globally. The issuance of this patent for crofelemer represents a step forward in the field of rare disease research and could potentially benefit patients around the world who are in need of new therapeutic options.

Conclusion

The issuance of a new patent for crofelemer by Napo Pharmaceuticals is a significant milestone in the field of rare disease treatment. This development not only strengthens the intellectual property protection for the drug but also holds the promise of providing new hope for patients with conditions like short bowel syndrome and bile acid diarrhea. Jaguar Health, Inc.’s dedication to innovation and patient care is evident in their continued efforts to bring novel treatments to market, and this patent is a testament to their commitment to making a difference in the lives of those with rare diseases.